The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib monotherapy in England using the existing data source, Cancer Analysis System (CAS).
Study Type
OBSERVATIONAL
Enrollment
1,540
oral therapy
oral therapy
Ipsen Facility
Slough, United Kingdom
Duration of therapy for the index treatments of interest stratified by line of therapy (LoT)
Duration of therapy will be measured from the initiation of the index treatment until the projected end date of the index treatment (or start of the subsequent therapy). (subgroups 1 to 4)
Time frame: From start of index treatment up to the end of treatment or start of subsequent therapy during data collection period (01 January 2011 and 31 January 2020)
Time between subsequent treatment lines
Time gap between the projected end date of the index treatment (cabozantinib or axitinib) until the start of the subsequent treatment. (subgroups 1 to 4)
Time frame: From baseline until the end of data collection period (01 January 2011 and 31 January 2020)
Sequencing of treatments (any treatments received from aRCC diagnosis until the end of follow up or death)
Treatment sequencing will be presented using a Sankey diagram that visualises the regimens received within each line of therapy and the number and percentage of patients who received those particular regimens.
Time frame: From baseline until the end of data collection period (01 January 2011 and 31 January 2020)
Time from aRCC diagnosis to initial SACT initiation
Defined as the time from diagnosis of aRCC until the start date of the first cycle of the SACT regimen (i.e., 1st LoT start). (subgroups 1 to 4)
Time frame: From baseline until the end of data collection period (01 January 2011 and 31 January 2020)
Time from RCC diagnosis to initial SACT initiation
Time from RCC diagnosis to initial SACT initiation will be defined as the time from diagnosis of RCC until the start date of the first cycle of the SACT regimen. (subgroups 1 to 4)
Time frame: From baseline until the end of data collection period (01 January 2011 and 31 January 2020)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time from RCC diagnosis to treatment initiation of cabozantinib
Time from diagnosis of RCC until the start of the first prescription of cabozantinib. (subgroups 1 and 3)
Time frame: From baseline until the end of data collection period (01 January 2011 and 31 January 2020)
Time from RCC diagnosis to treatment initiation of axitinib
Time from diagnosis of RCC until the start of the prescription of axitinib.
Time frame: From baseline until the end of data collection period (01 January 2011 and 31 January 2020)
Time from aRCC diagnosis to treatment initiation of cabozantinib
Time from diagnosis of aRCC until the start of the first prescription of cabozantinib. (subgroups 1 and 3)
Time frame: From baseline until the end of data collection period (01 January 2011 and 31 January 2020)
Time from aRCC diagnosis to treatment initiation of axitinib
Time from diagnosis of aRCC until the start of the first prescription of axitinib. (subgroups 2 and 4)
Time frame: From baseline until the end of data collection period (01 January 2011 and 31 January 2020)
Overall survival (OS)
Time from start of index treatment (cabozantinib/axitinib) until the date of death (from any cause) during the study period. (subgroups 1 to 4)
Time frame: From start of index treatment until death or end of data collection period (01 January 2011 and 31 January 2020 whichever occurs first
Landmark survival
Landmark survival will be defined as the time from start of the index treatment until date of death (from any cause) at specific time points (12, 18, and 24 months). (subgroups 1 to 4)
Time frame: 12 months
Landmark survival
Landmark survival will be defined as the time from start of the index treatment until date of death (from any cause) at specific time points (12, 18, and 24 months). (subgroups 1 to 4)
Time frame: 18 months
Landmark survival
Landmark survival will be defined as the time from start of the index treatment until date of death (from any cause) at specific time points (12, 18, and 24 months). (subgroups 1 to 4)
Time frame: 24 months
Time to next treatment (or death) (TTNT)
Time to next treatment (or death) (TTNT) will be defined as the time from start of index treatment until the start of the subsequent LoT (subgroups 1 to 4)
Time frame: From start of index treatment until the start of subsequent therapy during data collection period (01 January 2011 and 31 January 2020)
Time to treatment discontinuation (TTTD)
Time to treatment discontinuation (TTTD) will be defined as time from treatment initiation until treatment discontinuation or death. (subgroups 1 to 4)
Time frame: From start of index treatment until discontinuation or death during data collection period (01 January 2011 and 31 January 2020)